Melanoma

INGN 241 Gene Drug Demonstrates Tumor Growth Control

Published in Cancer Weekly, November 27th, 2001

Introgen Therapeutics, Inc., announced encouraging results from preclinical studies in melanoma using their INGN 241 gene drug.

The published studies were designed to answer two important questions in understanding the role of the mda-7 gene in skin cancer. First, how MDA-7 protein is regulated as tumors develop from benign moles to the full-blown skin cancer known as melanoma and, second, how overexpression of the mda-7 gene will affect melanoma cancer cell growth.

In the scientific publication, the researchers conclude that the MDA-7 protein is present in normal melanocytes (cells responsible for pigmentation in the skin) and early stages of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-11-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry